This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Endometrioid ovarian tumours

Authoring team

Exceptionally, carcinoma arises in endometriosis of the ovary.

More usually, tumours arise from the surface epithelium of the ovary whose histologic pattern closely resembles that of adenocarcinoma of the uterine endometrium.

Benign endometrioid tumours are rare and usually, a unilateral cystadenofibroma.

Malignant endometrioid adenocarcinoma is the second most common form of ovarian epithelial malignancy, accounting for 20-25% of all malignant ovarian neoplasms. Peak incidence is between 50 - 60 years of age. In early stage disease, they are bilateral in about 10% of cases.

Approximately 30% of endometrioid ovarian tumours coexist with a primary endometrial cancer. The tumours probably arise synchronously, rather than as metastases from other organs. About 10% of endometrioid ovarian tumours are associated with endometriosis.

Prognosis is better than for serous or mucinous ovarian tumours, possibly because many endometrioid tumours are well differentiated.

Reference

  1. Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: International Agency for Research on Cancer; 2014.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.